Research Details The study examined 193 patients with ovarian cancer treated at eight New York City hospitals. Just over 71 percent of the Black women with COVID-19 required hospitalization compared with 46 percent of non-Black patients. Of the 34 patients who died from COVID-19, 41.2 percent of them were Black.
Why It Matters The study analysis suggested that Black patients with COVID-19 had a higher prevalence of other health problems that contributed to their worsening COVID-19 infection. The underlying causes of racial disparities are multifactorial and include limited access to healthcare, [and] social determinants of health, racism, and discrimination. The COVID-19 pandemic has only heightened these and brought awareness, said senior author Bhavana Pothuri, MD, of NYU Langone Health in New York City.
E-Mail
A phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls. The final results were published online on Jan. 21 in
Cancer Discovery, a journal of the American Association for Cancer Research.
Advances in technology have made it possible for scientists and physicians to use information about the genetic makeup of a cancerous tumor to inform cancer treatment, but genetic heterogeneity the genetic variation between cancers in different patients and even between tumors within the same patient can make it difficult to determine the most effective targeting strategy for treating individual patients.
AACR and MPM award three grants to support groundbreaking cancer research projects
Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital.
The Transformative Cancer Research Grants Program provides generous funds to investigators so they can pursue innovative research which has the potential to help guide and advance cancer treatment and make a significant impact for cancer patients. These grants are part of OIF s impact program, which provides support for next-generation basic science research as well as patient access to oncology drugs through the UBS Optimus Foundation. OIF donates a percentage of the fund manager s profits to the impact program, as well as royalties on approved drugs from OIF startup portfolio com
E-Mail
PHILADELPHIA, PA and CAMBRIDGE, MA - January 19, 2021 Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital.
The Transformative Cancer Research Grants Program provides generous funds to investigators so they can pursue innovative research which has the potential to help guide and advance cancer treatment and make a significant impact for cancer patients. These grants are part of OIF s impact program, which provides support for next-generation basic science research as well as patient access to oncology drugs through the UBS Optimus Foundation. OIF donates a percentage of the fund manager s profits to the impact program, as well as royalties on approved drugs from OIF startup portfolio companies. To dat
Researchers define tumor invasion machinery orchestrated by a master cancer gene
Researchers investigated how cancer genes lead to the breakdown of the capsule that prevents cancerous cells from invading the surrounding healthy tissues and - find a hijacked molecular crowbar . The new findings help understand the mechanisms of cancer spreading and reveal a cancer vulnerability.
Researchers at the University of Helsinki have defined a cancer invasion machinery, which is orchestrated by a frequently mutated cancer gene called Ras. When signaling from Ras protein becomes abnormally high, like it does in many cancers, this switches on the cellular machinery that helps the cancer cells to depart from the tissue from which the cells have developed.